ReviewAmerican journal of physiology. Heart and circulatory physiology2012
Current perspectives on cardiac amyloidosis.
Review in American journal of physiology. Heart and circulatory physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 79 citations in OpenAlex.
- Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure.Scientific reports · 2019Trial
- Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2018Trial
- Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.International journal of hematology · 2017Trial
- Multimodality Imaging in Monoclonal Gammopathy of Undetermined Significance and ATTR Wild-Type Cardiac Amyloidosis.Life (Basel, Switzerland) · 2025Article
- The Prognostic Value of Platelet-to-Lymphocyte Ratio and Tricuspid Regurgitation Velocity in Patients with Light-Chain Myocardial Amyloidosis.Journal of inflammation research · 2025Article
- Case Report: A missed diagnosis of cardiac amyloidosis using echocardiography due to immunoglobulin light chain amyloidosis with normal wall thickness in the early stage.Frontiers in cardiovascular medicine · 2024Article
- Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis.Journal of clinical medicine · 2022Review
- Cardiac transthyretin amyloidosisEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma.Cureus · 2021Review
- Contemporary narrative review on left atrial strain mechanics in echocardiography: cardiomyopathy, valvular heart disease and beyond.Cardiovascular diagnosis and therapy · 2021Review
- The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis.Journal of clinical medicine · 2021Article
- Cardiac Amyloidosis Detected on Imaging of Patients with Heart Failure.The American journal of case reports · 2020Article
- Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study.Life (Basel, Switzerland) · 2020Article
- Left ventricular global function index by magnetic resonance imaging - a novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy.Scientific reports · 2020Article
- The Role of Multi-modality Imaging in the Diagnosis of Cardiac Amyloidosis: A Focused Update.Frontiers in cardiovascular medicine · 2020Review
- Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains.Biochemistry · 2019Article
- Histopathology in HCM.Global cardiology science & practice · 2018Review
- Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2018Observational
- Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.Scientific reports · 2017Article
- Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction.Arquivos brasileiros de cardiologia · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Amyloidosis represents a group of diseases in which proteins undergo misfolding to form insoluble fibrils with subsequent tissue deposition. While almost all deposited amyloid fibers share a common nonbranched morphology, the affected end organs, clinical presentation, treatment strategies, and prognosis vary greatly among this group of diseases and are largely dependent on the specific amyloid precursor protein. To date, at least 27 precursor proteins have been identified to result in either local tissue or systemic amyloidosis, with nine of them manifesting in cardiac deposition and resulting in a syndrome termed "cardiac amyloidosis" or "amyloid cardiomyopathy." Although cardiac amyloidosis has been traditionally considered to be a rare disorder, as clinical appreciation and understanding continues to grow, so too has the prevalence, suggesting that this disease may be greatly underdiagnosed. The most common form of cardiac amyloidosis is associated with circulating amyloidogenic monoclonal immunoglobulin light chain proteins. Other major cardiac amyloidoses result from a misfolding of products of mutated or wild-type transthyretin protein. While the various cardiac amyloidoses share a common functional consequence, namely, an infiltrative cardiomyopathy with restrictive pathophysiology leading to progressive heart failure, the underlying pathophysiology and clinical syndrome varies with each precursor protein. Herein, we aim to provide an up-to-date overview of cardiac amyloidosis from nomenclature to molecular mechanisms and treatment options, with a particular focus on amyloidogenic immunoglobulin light chain protein cardiac amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.